Effects of antihypertensive drugs on coronary artery disease risk: A meta-analysis

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 6-7, 1996, Pages 555-558

  Howes, L G ^a   Lykos, D ^c   Rennie, G C ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b OR Systems Pty Ltd   (Australia)

^c NONE

Author keywords

ACE inhibitors; Beta blocker; Calcium antagonist; Cardiovascular risk factors; Hypertension; adrenoceptor antagonist; 1 adrenoceptors; 2 adrenoceptors

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELIPROLOL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY DISEASE; HUMANS; HYPERTENSION; LIPIDS; RISK FACTORS;

EID: 0029885524     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb02778.x     Document Type: Article

References (12)

1. Ballantyne D. Long-term effects of antihypertensives on blood lipids. J. Hum. Hypertens. 1990; 4 (Suppl. 2): 35-7.
2. Cruickshank JM, Prichard BNC. Beta-blockers in Clinical Practice. Churchill Livingstone, Edinburgh. 1988.
3. Betteridge DJ. Doxazosin and lipid and lipoprotein metabolism. Rev. Contemp. Pharmacother. 1992; 3: 9-12.
4. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-62.
5. Van Brummelen P. The relevance of intrinsic sympathomimetic activity for beta-blocker-induced changes in plasma lipids. J. Cardiovasc. Pharmacol. 1983; 5 (Suppl. 1): S51-5.
6. Ames TP. The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic antihypertensive drugs. Drugs 1986; 32: 335-57.
7. Landmark K. Antihypertensive and metabolic effects of long term therapy with nifedipine slow-release tablets. J. Cardiovasc. Pharmacol. 1985; 7: 12-17.
8. Weinberger MH. Influence of an angiotensin converting enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5: 132-8.
9. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ 1992; 304: 405-12.
10. Medical Research Council Working Party. Medical Research Council trail of treatment of mild hypertension: Principal results. BMJ 1985; 291: 97-104.
11. Luiz W, Wiemer G, Scholkens BA. ACE inhibition induces NO formation in cultured bovine endothelial hearts. J. Mol. Cell Cardiol. 1992; 24: 909-19.
12. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.